Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
91.17
+0.11 (0.12%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.

Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc.
Nuvalent logo
Country United States
Founded 2017
IPO Date Jul 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 92
CEO James Porter

Contact Details

Address:
One Broadway, 14th Floor
Cambridge, Massachusetts 02142
United States
Phone 857 357 7000
Website nuvalent.com

Stock Details

Ticker Symbol NUVL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001861560
CUSIP Number 670703107
ISIN Number US6707031075
SIC Code 2834

Key Executives

Name Position
Dr. James R. Porter Ph.D. Chief Executive Officer, President and Director
Prof. Matthew D. Shair Ph.D. Founder, Head of Scientific Advisory Board and Director
Alexandra Balcom CPA, M.B.A. Chief Financial Officer and Treasurer
Dr. Christopher D. Turner M.D. Chief Medical Officer
Dr. Benjamin Lane Ph.D. Senior Vice President of Technical Operations
Henry Pelish Ph.D. Chief Scientific Officer
Deborah Ann Miller J.D., Ph.D. Chief Legal Officer and Secretary
Matthew Metivier Senior Vice President of Human Resources
Darlene Noci Chief Development Officer
John Soglia Ph.D. Senior Vice President of Translational Development

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 144 Filing
Oct 22, 2024 144 Filing
Oct 15, 2024 144 Filing
Oct 1, 2024 144 Filing